Anasens is a disruptive start-up (deep tech) developing an innovative quantitative and connected molecular detection platform for blood or saliva analysis, at home or at a point of service, in less than 5 minutes. Anasens is pioneering DNA-based electrochemical nanosensors for rapid, point-of-care detection. Their platform enables quantitative detection of biomarkers, drugs, and proteins in saliva or blood within minutes. Anasens increases accessibility to precision medicine by offering lab-quality testing that can be done when and where it matters. The company is supported by academic & industry leadership, multiple grants, and a growing IP portfolio.
Co-Founder and CSO
Chief Operating Officer
Co-Founder & Advisory Chief Product Officer
VP Strategy
We use essential cookies to make this site work. With your permission, we'd also like to use analytics cookies to understand how people use the site, and marketing cookies to measure our outreach. You can change your choice any time. Privacy policy
Choose which cookies you allow. Essential cookies are always on because the site can't work without them.
Keep the site secure, remember your cookie choice and make core features work.
Help us understand which pages are visited and how people find us (Google Analytics). Data is aggregated.
Measure our campaigns and show relevant content on other platforms (e.g. Google Ads, LinkedIn, Meta).